Literature DB >> 15868434

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.

Huei-Jean Huang1, Patrick Neven, Maria Drijkoningen, Robert Paridaens, Hans Wildiers, Erik Van Limbergen, Patrick Berteloot, Frederic Amant, Marie Rose Christiaens, Ignace Vergote.   

Abstract

In oestrogen receptor-positive (ER+) breast cancer, HER-2/neu and the progesterone receptor (PR) are inversely associated. This explains a lower response to anti-oestrogens if ER+ breast cancers are HER-2/neu positive. One randomized study however, showed that premenopausal women with an ER+ breast cancer respond to anti-oestrogens independent of HER-2/neu. We therefore hypothesized an age-related association between HER-2/neu and PR in ER+ breast cancers. Receptors for ER, PR and HER-2/neu were analysed by immunohistochemistry (IHC). A uni- and multivariate analyses was carried out to assess this relationship in 1104 women with an ER+ breast cancer. We observed an inverse association between HER-2/neu and PR only after age 45. There were 173 women of age<or=45 and 931 of age>45 years. In multivariate analysis, only tumour grade (p=0.005) but not PR status was associated with HER-2/neu in women age<or=45 years. However, in age>45 years group, both PR status (p=0.001) and tumour grade (p=0.001) were independently associated with HER-2/neu. In ER+ breast cancers from women age>45, PR was positive in 76.9% if HER-2/neu negative but in 53.4% if HER-2/neu positive (p<0.001) and the median quantitative PR levels are 150 and 75 respectively in HER-2/neu negative and HER-2/neu positive tumours (p=0.002). This age effect of HER-2/neu on the PR status was not seen in women age<or=45 years and the median quantitative PR levels are 200 and 220 respectively in HER-2/neu negative and HER-2/neu positive tumours (p=0.518). The study confirms an age-related inverse relationship between HER-2/neu and PR only in women age>45 years but not in women age<or=45 years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868434     DOI: 10.1007/s10549-004-8235-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  The protective effect of parity in hormone receptor-positive, Ki-67 expressing breast cancer.

Authors:  Se Kyung Lee; Seok Won Kim; Sang-Ah Han; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

2.  Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.

Authors:  Kathleen A Cronin; Linda C Harlan; Kevin W Dodd; Jeffrey S Abrams; Rachel Ballard-Barbash
Journal:  Cancer Invest       Date:  2010-11       Impact factor: 2.176

3.  Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.

Authors:  Shu-Fang Ning; Ji-Lin Li; Cheng-Piao Luo; Chang-Hong Wei; Yong-Kui Lu; Hai-Zhou Liu; Wen-E Wei; Li-Tu Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

Review 4.  A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.

Authors:  Ainhoa Arana Echarri; Mark Beresford; John P Campbell; Robert H Jones; Rachel Butler; Kenneth J Gollob; Patricia C Brum; Dylan Thompson; James E Turner
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561

5.  In vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells.

Authors:  Francesca De Amicis; Alessandra Russo; Paola Avena; Marta Santoro; Adele Vivacqua; Daniela Bonofiglio; Loredana Mauro; Saveria Aquila; Donatella Tramontano; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Mol Nutr Food Res       Date:  2013-01-16       Impact factor: 5.914

6.  Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter.

Authors:  F De Amicis; S Zupo; M L Panno; R Malivindi; F Giordano; I Barone; L Mauro; S A W Fuqua; S Andò
Journal:  Mol Endocrinol       Date:  2009-01-15

Review 7.  Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.

Authors:  Jing Peng; Surojeet Sengupta; V Craig Jordan
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

8.  Factors that influence the incidence of breast cancer in Arica, Chile (Review).

Authors:  Gloria M Calaf; Fresia Caba; Jorge Farias; Francisco Rothhammer
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

9.  HER-2/Neu and Hormone Receptor Analysis in Breast Carcinomas and Their Association with Clinicopathologic Parameters.

Authors:  Reşit Doğan Köseoğlu; Fatma Markoç; Ahmet Müslehiddinoğlu; Ayşe Burcu İleri; Faik Alev Deresoy; İlker Etikan
Journal:  Eur J Breast Health       Date:  2018-10-24

10.  A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis.

Authors:  Patrick Neven; Toon Van Gorp; Karen Deraedt
Journal:  Breast Cancer Res       Date:  2008-09-04       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.